Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-1-7
pubmed:abstractText
To obtain long-term engraftment and hematopoiesis in myeloablated patients, the cell population used for hematopoietic reconstitution should include a sufficient number of early pluripotent hematopoietic stem cells (HSCs), along with committed cells from the various lineages. For this purpose, the small subset of CD34+ cells purified from different sources must be expanded ex vivo. Since cytokines may induce both proliferation and differentiation, expansion would provide a cell population comprising committed as well as uncommitted cells. Optimization of HSC expansion methods could be obtained by a combination of cytokines able to sustain renewal of pluripotent cells yet endowed with poor differentiation potential. We used variations of the combinations of cytokines described by Brugger et al. [W. Brugger, S. Heimfels, R. J. Berenson, R. Mertelsmann, and L. Kanz (1995) N. Engl. J. Med. 333, 283-287] and Piacibello et al. [W. Piacibello, F. Sanavio, L. Garetto, A. Severino, D. Bergandi, J. Ferrario, F. Fagioli, M. Berger, and M. Aglietta (1997) Blood 89, 2644-2653] to expand UCB CD34+ cells and monitored proliferation rate and phenotype after 14 days of culture. Several hematopoietic lineage-associated surface antigens were evaluated. Our data show that flt3L and thrombopoietin in combination with IL-3, while sustaining a high CD34+ proliferation rate, provide a relatively low enrichment in very early uncommitted CD34+/CD38- cells. Conversely, in the absence of IL-3, they are less effective in inducing proliferation yet significantly increase the number of CD34+/CD38- cells. A combination of the above protocols, applied simultaneously to aliquots of the same sample, would allow expansion of both committed and pluripotent HSC. This strategy may represent a significant improvement for clinical applications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/ADP-ribosyl Cyclase, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD38, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation, http://linkedlifedata.com/resource/pubmed/chemical/CD38 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/NAD Nucleosidase, http://linkedlifedata.com/resource/pubmed/chemical/Stem Cell Factor, http://linkedlifedata.com/resource/pubmed/chemical/Thrombopoietin, http://linkedlifedata.com/resource/pubmed/chemical/flt3 ligand protein
pubmed:status
MEDLINE
pubmed:issn
1079-9796
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
715-24; discussion 725-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11778655-ADP-ribosyl Cyclase, pubmed-meshheading:11778655-Antigens, CD, pubmed-meshheading:11778655-Antigens, CD34, pubmed-meshheading:11778655-Antigens, CD38, pubmed-meshheading:11778655-Antigens, Differentiation, pubmed-meshheading:11778655-Cell Culture Techniques, pubmed-meshheading:11778655-Cell Differentiation, pubmed-meshheading:11778655-Cell Division, pubmed-meshheading:11778655-Drug Synergism, pubmed-meshheading:11778655-Erythropoietin, pubmed-meshheading:11778655-Fetal Blood, pubmed-meshheading:11778655-Flow Cytometry, pubmed-meshheading:11778655-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11778655-Hematopoietic Stem Cells, pubmed-meshheading:11778655-Humans, pubmed-meshheading:11778655-Immunomagnetic Separation, pubmed-meshheading:11778655-Immunophenotyping, pubmed-meshheading:11778655-Infant, Newborn, pubmed-meshheading:11778655-Interleukin-3, pubmed-meshheading:11778655-Interleukin-6, pubmed-meshheading:11778655-Membrane Glycoproteins, pubmed-meshheading:11778655-Membrane Proteins, pubmed-meshheading:11778655-NAD+ Nucleosidase, pubmed-meshheading:11778655-Stem Cell Factor, pubmed-meshheading:11778655-Thrombopoietin
pubmed:articleTitle
A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use.
pubmed:affiliation
Dideco SpA, Mirandola, Italy.
pubmed:publicationType
Journal Article, Comparative Study